Haemonetics (HAE) Expected to Announce Earnings on Thursday

Haemonetics (NYSE:HAE) is anticipated to issue its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $331.8980 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. Haemonetics’s revenue for the quarter was down 5.3% on a year-over-year basis. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Stock Down 2.6%

HAE opened at $66.10 on Thursday. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of 19.33, a price-to-earnings-growth ratio of 1.41 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The firm’s fifty day moving average is $78.90 and its 200 day moving average is $65.57. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Haemonetics by 20,925.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 837 shares in the last quarter. CIBC Private Wealth Group LLC raised its position in shares of Haemonetics by 69.3% in the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 448 shares during the last quarter. Quadrant Capital Group LLC purchased a new position in shares of Haemonetics in the third quarter worth about $76,000. Finally, Strs Ohio acquired a new position in Haemonetics during the first quarter worth about $140,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Raymond James Financial reissued an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. Barrington Research boosted their price objective on shares of Haemonetics from $90.00 to $93.00 and gave the company an “outperform” rating in a research report on Monday, January 12th. Citigroup lowered their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Finally, CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $84.40.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.